Perry T, Greig NH
DREAMS-3 is the world's first Phase 3 clinical trial of a GCG/GLP-1 dual receptor agonist to conduct a head-to-head comparison with Semaglutide in diabetes treatment
Research has identified these receptors in the hippocampus, amygdala, prefrontal cortex, and brainstemareas integral to memory, emotional processing, executive function, and autonomic regulation
At any age, a whole-person approach to weight management is ideal, and this approach can be especially helpful for women in perimenopause, menopause, and postmenopause
The overall matched cohorts contained 47,199 patients per arm and were closely balanced for age at the index event (59.4 versus 59.9 years), female representation (62.8% versus 61.3%), baseline BMI (35.6 versus 35.3 kg/m 2 ), and baseline documented type 2 diabetes prevalence (25.8% versus 26.0%) (Table 2)